First Patient Enrolled in FDA Phase 1/2a Clinical Trial with BioLight’s Controlled-Release Latanoprost Insert for the Treatment of Glaucoma

BioLight announces that the first patient has been enrolled in the U.S. into a FDA Phase 1/2a clinical trial with Eye-D®, the company’s controlled-release latanoprost insert for the treatment of glaucoma.

Link to the complete article

Link to Newsroom

Comments are closed